By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Paris-based Cellectis today said that it has licensed to Harvard Bioscience division Harvard Apparatus exclusive, worldwide rights to manufacture and sell electroporation-based instruments owned by the firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.